1

CURRICULUM VITAE Updated June, 2018

1. PERSONALIA Name Jan Pruim Department of Nuclear medicine, Medical Imaging Center Groningen University Medical Center Groningen PO Box 30.001 9700 RB Groningen, the Netherlands Private address Meeuwstraat 8 9791 GE Ten Boer The Netherlands Telephone 0031-503021327 Mobile Phone 0031-655150779 E-mail j.pruim@umcg.nl Nationality Dutch Date and place of birth March 31 1958, Smallingerland Gender Male Medical registration

• Dutch registration (5-yearly): Registratiecommissie Geneeskundig Specialismen (RGS) o BIG number 89023363901 o Specialist registration

§ First registration 1-7-2000, renewed till 1-7-2020

2. TRAINING

2.1 FORMAL TRAINING 1994, May 18 PhD- thesis Organ donation for transplantation: a clinical study with emphasis on liver donation. Supervisor: Slooff MJH. Co-supervisor: ten Vergert EM. University of Groningen, May 18, 1994. 2000, July 1 Registration as Nuclear Medicine specialist, University Medical Center Groningen

2

1997 Certificate in Radiation Protection, University of Groningen 1976-1985 MD, University of Groningen, The Netherlands 1976 High School, Graduation Atheneum-B, Ichthus College, Drachten, The Netherlands

2.2 COURSES AND CERTIFICATES - Continuing education (last 5 year) Professionally Participation in national and international congresses, e.g. Radiological Society of North-America (RSNA), Society of Nuclear Medicine and Molecular Imaging (SNMMI), European Association of Nuclear Medicine (EANM), World Federation of Nuclear Medicine and Biology (WFNMB) and Scientific Meetings of the Dutch Society of Nuclear Medicine. For details see GAIA records.

Interdisciplinary 2017 Recertification BROK. 2015 Teach the Teacher III 2015 University Teaching Qualification (“Basis Kwalificatie Onderwijs”) 2014 United Nations Department of Safety and Security: Advanced Security in the

Field 2014 United Nations Department of Safety and Security: Basic Security in the Field II 2013 BROK (Basiscursus Regelgeving en Organisatie voor Klinisch Onderzoekers/Basic

Course on Regulations and Organisation for Clinical Investigators) Certificate, score 86%.

2012 Teach the Teacher II 2011 Teach the Teacher I

2.3 LANGUAGES

understanding reading speaking writing Dutch Mother tongue Mother tongue Mother tongue Mother tongue English +++ +++ +++ +++ French + + + + German +++ ++ +++ ++

3. FUNCTIONS HELD and ACHIEVEMENTS

3.1 FUNCTIONS HELD 2017 Chair European School for Multimodality Imaging and Therapy (ESMIT)/Member of

the Board of the European Association for Nuclear Medicine annex Board Member of the European Association for Nuclear Medicine

3

2017 Chair Central Training Committee (‘Centrale Opleidingscommissie’), University

Medical Center Groningen 2015 Principal Manager Residency Program Dept. of Radiology and Nuclear Medicine

(CORONA), University Medical Center Groningen, The Netherlands

2013-2016 Vice-president of the Dutch Society of Nuclear Medicine.

2012 2011-2015

Appointment as Extraordinary Professor of Nuclear Medicine at Stellenbosch University, Tygerberg Hospital, Stellenbosch/Cape Town, South-Africa. Principal Manager (“Opleider”) of Nuclear Medicine residents at the University Medical Centre Groningen

2009

Appointment as Associate Professor, University of Groningen

2006-2011

Deputy Manager (“Plaatsvervangend Opleider”) of Nuclear Medicine residents at the University Medical Centre Groningen

1997-2000

Resident Nuclear Medicine, Groningen University Hospital, Groningen, The Netherlands

1991-2003

Head of Biomedical Group and staff member PET-Centre, Groningen University Hospital, Groningen, The Netherlands

1990

Clinical Reviewer, Dutch Medicines Evaluation Board, The Hague, The Netherlands

1986-1990

Transplant Co-ordinator, Dept. of Surgery, Groningen University Hospital, Groningen, The Netherlands

1985

Resident in Surgery (not in training, ‘AGNIO’), Dept. of Surgery, Groningen University Hospital, Groningen, The Netherlands

1985

Principal Investigator Pharma Bio Research (now PRA International), Assen, The Netherlands

2014 Appointment as Full Professor of Medical Imaging (especially hybrid imaging based on positron emission tomography)

2014 Vice-Chair European School for Nuclear Medicine (ESNM)

2014 IAEA Expert. IAEA/Malaysian Ministry of Science, Technology and Innovation/Malaysian Nuclear Agency. Topic: Improving Human Resource Skills in Hybrid Imaging. Expert Mission on the Clinical Role of Hybrid Imaging.

4

3.2 ACHIEVEMENTS From the beginning of my career I have been working in dynamic environments that asked a lot of improvisation and/or pioneering. I am proud of having been a member of the teams that I worked with. Mostly, I am proud on the development of the PET-Center in Groningen from the first center in the country to the current part of the Medical Imaging Center of the UMCG. Without hesitation I dare to say that the facilities, the people and the output belong to the best in Europe and probably even the world.

4. PATIENT CARE AND MANAGEMENT

4.1 FUNCTIONS WITHIN THE UNIVERSITY MEDICAL CENTER

- Care activities: reporting of PET/CT’s predominantly in Oncology. Consultant during multidisciplinary oncology meetings. Emphasis on lung cancer, lymphoma, oesophagela cancer, prostate cancer and head-neck cancer.

- Research activities: see below. In summary the use of FDG-PET in oncology including cost-effectiveness.

- Educational activities: providing lectures for medical and pharmacy students at different time points in their studies.

- Training: (deputy) trainer of Nuclear Medicine; trainer of Radiology; chair Central Training Committee

4.2 EXTERNAL PROFESSIONAL ACTIVITIES (outside UMCG)

2015- Member of the Chamber Radiology of the Permanent Visitation

Commission of the Medical Specialists Registration Committee of the Royal Dutch Medical Society

2015- Member Concilium Radiologicum

2013-2015 Member CORONA (=Comité Opleidingsvernieuwing Radiologie en Nucleaire Geneeskunde), the committee that developed the national curriculum for an integrated training in Radiology and Nuclear Medicine

2009 Member of the Imaging Group of the European Organisation for the Research and Treatment of Cancer (EORTC)

2009-2015 Chairman of the Chamber Nuclear Medicine of the Permanent Visitation Commission of the Medical Specialists Registration Committee of the Royal Dutch Medical Society

2009 Member of the Scientific Committee of the Annual Congress of the European Association of Nuclear Medicine

2008-2016 Member of the Appeal Advisory Board of the Royal Dutch Medical Society

5

(on behalf of the Dutch Society for Nuclear Medicine)

1998-2000 Member of the Task Group on Guideline Development for Diagnosis and Treatment of Breast Cancer. Dutch Institute for Healthcare Improvement (CBO) (on behalf of the Dutch Society for Nuclear Medicine)

1985-2005 Member Medical Ethics Committee, Foundation for Judgment on Medical Ethics, Assen, The Netherlands

5. TRAINING

6. TEACHING

Also: lecturer on Nuclear Medicine for the Faculty of Medical Sciences and Subfaculty of Pharma-cology, University of Groningen (medical students, pharmacology students); for the School for Medical Imaging and Radiotherapeutic Techniques (MBRT), Hanzehogeschool Groningen, and the Education Days of the Dutch Society of Nuclear Medicine.

6.1 ORGANISATION OF SYMPOSIA AND CONFERENCES - Beyond FDG. Symposium on PET Radiopharmaceuticals. Groningen, April 3-5, 2014. - IRIST, 20th Meeting of the International Research Group in Immuno-Scintigraphy and Therapy.

Groningen, April 7-10, 2010.

2015-

Appointment as Principal Trainer (“Opleider”) of Radiology residents at the University Medical Centre Groningen (after the merger with Nuclear Medicine).

2013-

Member of the CORONA Committee, a committee of the Dutch Society of Nuclear Medicine and the Dutch Radiological Society to create an integrated residency for trainees.

2012- Member of the Task Group Discipline Surpassing Education, branch Imaging, of the UMCG.

2011-

Appointment as Principal Trainer (“Opleider”) of Nuclear Medicine residents at the University Medical Centre Groningen

2012 Co-anchor e-learning course on PET/CT in Oncology of the European Society of Nuclear Medicine.

2011- Member of the Educational Committee, Oncology branch, of the European association of Nuclear Medicine (EANM)

2004-current

Moderator at the PET/CT-course in Oncology of the European Association of Nuclear Medicine (EANM) (approx. 3 times in 2 years). The basic and advanced courses of the EANM provide trainees, radiologists and nuclear medicine physicians with the latest information about the use of PET/CT in clinical practice and research.

2003-2009 Member of the Education Committee of the Dutch Society for Nuclear Medicine. Task of the Committee is to develop the national curriculum and examinations for trainees in nuclear medicine.

6

- Member of the Scientific Committee of the Annual Congress of the European Association of Nuclear Medicine, Barcelona, October 10-14, 2009.

- Symposium on Molecular Imaging in Drug Discovery. Groningen, April 23-24, 2009. - Symposium Nuclear Medicine Methods for the Study of Inflammatory Processes and Infection.

Groningen, May 22-23, 2008. - Symposium Molecular Imaging for Diagnosis and Prediction of Treatment Outcome. International

Symposium on the Occasion of 30 years of PET in Groningen. Groningen, September 13-14, 2007. - Symposium Physics meets Nuclear Medicine: Back to the Future. Groningen, October 18, 2006. - Symposium Small Animal Imaging: Bridging the Gap between Laboratory and Clinic. Groningen,

May 15-16, 2006. - Pioneering Evaluating Translating. Afscheidssymposium prof.dr. W. Vaalburg. Groningen,

September 17, 2004. - European Conference on Research and Application of Positron Emission Tomography in Oncology.

Groningen, April 17-19, 1996

7. RESEARCH

7.1 MAJOR RESEARCH LINES 1. The use of positron emission tomography in clinical practice, especially in oncology. Cost-

effective-ness of applying the method in cancer staging and therapy evaluation. Technical improvements of the technique especially in relation to radiotherapeutic planning.

2. Planning of duties of residents: finding the balance between training, hospital management and personal life.

7.2 PUBLICATIONS Full papers H-factor (Web of Science): 45 2018 1. Tc-99m-HDP bone scintigraphy and F-18-sodiumfluoride PET/CT in primary staging of patients

with prostate cancer. Wondergem M, van der Zant FM, Knol RJJ, Burgers AMG, Bos SD, de Jong IJ, Pruim J. World J Urol 2018;36(1):27-34.

2017 2. 18F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes ; detection rate,

image quality, activity kinetics and biodistribution. Wondergem M, van der Zant F, Knol R, Lazarenko S, Pruim J, de Jong IJ. J Nucl Med. 2017:58(11);1797-1804.

2016 3. An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA

PET/CT in patients with advanced non-small-cell lung cancer (NSCLC). Kerner GS, Bollineni VR, Hiltermann TJ, Sijtsema NM, Fischer A, Bongaerts AH, Pruim J, Groen HJ. EJNMMI Res. Dec;6(1):33. doi: 10.1186/s13550-016-0187-6. Epub 2016 Apr 18.

4. Impact of fasting on (18)F-fluorocholine gastrointestinal uptake and detection of lymph node metastases in patients with prostate cancer. Wondergem M, van der Zant FM, Knol RJ, Pruim J, de Jong IJ. EJNMMI Res. 2016 Dec;6(1):2. doi: 10.1186/s13550-015-0159-2. Epub 2016 Jan 6.

7

5. Effectiveness of an (18)F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. de Bree R, van der Putten L, van Tinteren H, Wedman J, Oyen WJ, Janssen LM, van den Brekel MW, Comans EF, Pruim J, Takes RP, Hobbelink MG, Valdés Olmos R, van der Laan BF, Boers M, Hoekstra OS, Leemans CR. Radiother Oncol. 2016 Feb;118(2):251-6. doi: 10.1016/j.radonc.2015.10.010. Epub 2015 Oct 20.

6. Value of EUS in Determining Curative Resectability in Reference to CT and FDG-PET: The Optimal Sequence in Preoperative Staging of Esophageal Cancer? Schreurs LM, Janssens AC, Groen H, Fockens P, van Dullemen HM, Berge Henegouwen MI, Sloof GW, Pruim J, van Lanschot JJ, Steyerberg EW and Plukker JT. Ann Surg Oncol 2016 Dec;23(Suppl 5):1021-1028.

2015 7. Assessment of hypoxic subvolumes in laryngeal cancer with F-18-fluoroazomycinarabinoside

(F-18-FAZA)-PET/CT scanning and immunohistochemistry Leonie Bruine de Bruin, Vikram R. Bollineni, Jan E. Wachters, Ed Schuuring, Bettien M. van Hemel, Jacqueline E. van der Wal, Lorian Slagter-Menkema, Geertruida H. de Bock, Roel J.H.M. Steenbakkers, Johannes A. Langendijk, Jan Pruim, Bernard F.A.M. van der Laan, Gyorgy B. Halmos. Radiother Oncol 2015;117:106-112

8. Evaluation of elastix-based propagated align algorithm for VOI- and voxel-based analysis of longitudinal F-18-FDG PET/CT data from patients with non-small cell lung cancer (NSCLC) Kerner, Gerald S.M.A.; Fischer, Alexander; Koole, Michel J.B.; Pruim, Jan; Groen, Harry J.M. EJNMMI Res 2015;5:15.

9. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Boellaard, R; Delgado-Bolton, R; Oyen, WJG; Giammarile, F; Tatsch, K; Eschner, W; Verzijlbergen, FJ; Barrington, SF; Pike, LC; Weber, WA; Stroobants, S; Delbeke, D; Donohoe, KJ; Holbrook, S; Graham, MM; Testanera, G; Hoekstra, OS; Zijlstra, J; Visser, E; Hoekstra, CJ; Pruim, J; Willemsen, A; Arends, B; Kotzerke, J; Bockisch, A; Beyer, T; Chiti, A; Krause, BJ. Eur J Nucl Med Molec Imaging 2015;42 (2);328-354; DOI: 10.1007/s00259-014-2961-x

2014 10. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol

Imaging. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ. 2014 Dec 2. [Epub ahead of print]

11. Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer. Muijs CT, Beukema JC, Woutersen D, Mul VE, Berveling MJ, Pruim J, van der Jagt EJ, Hospers GA, Groen H, Plukker JT, Langendijk JA. Radiother Oncol. 2014 Nov;113(2):188-92. doi: 10.1016/j.radonc.2014.10.016.

12. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Bollineni VR, Koole MJ, Pruim J, Brouwer CL, Wiegman EM, Groen HJ, Vlasman R, Halmos GB, Oosting SF, Langendijk JA, Widder J, Steenbakkers RJ. Radiother Oncol. 2014 Nov;113(2):198-203. doi: 10.1016/j.radonc.2014.10.010.

13. Prostate involvement of systemic granulomatous disease, demonstrated by 18F-FDG PET/CT. Stormezand GN, Slart RHJA, Glaudemans AWJM, Pruim J. Tijdschr Nucl Geneeskd 2014

8

Sep;36(3):1286. 14. First clinical results of (d)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with

non-small cell lung cancer and head and neck squamous cell carcinoma. Burger IA, Zitzmann-Kolbe S, Pruim J, Friebe M, Graham K, Stephens A, Dinkelborg L, Kowal K, Schibli R, Luurtsema G, Maas B, Horn-Tutic M, Haerle SK, Wiegers J, Schaefer NG, Hany TF, von Schulthess GK. J Nucl Med. 2014 Nov;55(11):1778-85. doi: 10.2967/jnumed.114.140699.

15. Prognostic Impact of Clinicopathological Features and Expression of Biomarkers Related to 18F-FDG Uptake in Esophageal Cancer. Schreurs LMA, Smit JK, Pavlov K, Pultrum BB, Pruim J, Groen H, Hollema H, Plukker JTM. Ann Surg Oncol. DOI 10.1245/s10434-014-3848-6.

16. Validity of bioelectrical impedance analysis to assess fat-free mass in patients with head and neck cancer: an exploratory study. Jager-Wittenaar H, Dijkstra PU, Earthman CP, Krijnen WP, Langendijk JA, van der Laan BF, Pruim J, Roodenburg JL. Head Neck. 2014 Apr;36(4):585-91. doi: 10.1002/hed.23336.

17. Head and neck tumor hypoxia imaging by 18F-Fluoroazomycin-arabinoside (18F-FAZA)-PET: a review. Halmos GB, de Bruin LB, Langendijk JA, van der Laan BF, Pruim J, Steenbakkers RJ. Clin Nucl Med. 2014 Jan;39(1):44-8. doi: 10.1097/RLU.0000000000000286.

2013 18. Teaching neuroimages: FDG-PET imaging in primary diffuse leptomeningeal gliomatosis.

Weijenberg A, van Dijk JM, Pruim J, Luijckx GJ. Neurology. 2013 Oct 15;81(16):e119-20. doi: 10.1212/WNL.0b013e3182a840db.

19. Application of 99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: A first-in-man study. Ananias HJ, Yu Z, Hoving HD, Rosati S, Dierckx RA, Wang F, Yan Y, Chen X, Pruim J, Lub-de Hooge MN, Helfrich W, Elsinga PH, de Jong IJ. Nucl Med Biol. 2013 Oct;40(7):933-8. doi: 10.1016/j.nucmedbio.2013.05.009.

20. Small-Animal PET with a σ-Ligand, 11C-SA4503, Detects Spontaneous Pituitary Tumors in Aged Rats. Ramakrishnan NK, Rybczynska AA, Visser AK, Marosi K, Nyakas CJ, Kwizera C, Sijbesma JW, Elsinga PH, Ishiwata K, Pruim J, Dierckx RA, van Waarde A. J Nucl Med. 2013;54(8):1377-83.doi: 10.2967/jnumed.112.115931.

21. Alternative PET tracers in head and neck cancer. A review. Wedman J, Pruim J, Roodenburg JL, Halmos GB, Langedijk JA, Dierckx RA, van der Laan BF. Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2595-601. doi: 10.1007/s00405-012-2316-9.

22. PET Imaging of Tumor Hypoxia Using 18F-Fluoroazomycin Arabinoside in Stage III-IV Non-Small Cell Lung Cancer Patients. Bollineni VR, Kerner GS, Pruim J, Steenbakkers RJ, Wiegman EM, Koole MJ, de Groot EH, Willemsen AT, Luurtsema G, Widder J, Groen HJ, Langendijk JA. J Nucl Med. 2013 Aug;54(8):1175-80

23. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of (11)C-choline positron emission tomography in recurrent prostate cancer. Rybalov M, Breeuwsma AJ, Leliveld AM, Pruim J, Dierckx RA, de Jong IJ. World J Urol 2013 Apr;31(2):319-23

24. Oesophageal tumour progression between the diagnostic ¹⁸F-FDG-PET and the ¹⁸F-FDG-PET for radiotherapy treatment planning. Muijs CT, Pruim J, Beukema JC, Berveling MJ, Plukker JT, Langendijk JA. Radiother Oncol. 2013 Mar;106(3):283-7. doi: 10.1016/j.radonc.2012.10.015.

2012 25. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men

with recurrent prostate cancer after radical prostatectomy. Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ. Q J Nucl Med Mol Imaging. 2012 Oct;56(5):440-6.

9

26. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; N Engl J Med 2012 May 31;366(22):2074-84.

27. Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: Implications for radiotherapy. Bollineni VR, Wiegman EM, Pruim J, Groen HJ, Langendijk JA. Cancer Treat Rev 2012 Dec;38(8):1027-32.

28. Residual (18)F-FDG-PET Uptake 12 Weeks after Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control. Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e551-5.

29. [11C]choline PET for the intraprostatic tumor characterization and localization in recurrent prostate cancer after EBRT. Rybalov M, Breeuwsma AJ, Pruim J, Leliveld AM, Rosati S, Veltman NC, Dierckx RA, De Jong IJ. Q J Nucl Med Mol Imaging 2012;56(2):202-8.

30. Plasma thymus and antigen-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma. Plattel WJ, van den Berg A, Visser L, van der Graaf AM, Pruim J, Vos H, Hepkema B, Diepstra A, van Imhoff GW. Haematologica 2012;97(3):410-5.

2011 31. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging

markers derived from PET and dynamic contrast-enhanced MRI. de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruim J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ and Hoekstra OS. J Nucl Med 2011;52:48-55.

32. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Dingemans AM, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HT, van Tinteren H, Hoekstra OS, Pruim J, Brans B, Thunnissen FB, Smit EF and Groen HJ. Ann Oncol 2011;22:559-566.

33. Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Fanti S, Krause B, Weber W, Castellucci P, Grosu AL, de J, I, Messa C, Picchio M, Pruim J, Langsteger W and Chiti A. Eur Urol 2011;59:572-83. Eur Urol 2011;60:e37-e38.

34. Panniculitis-like T-cell lymphoma detected by positron emission tomography/computed tomography scanning in a patient with haemophagocytic syndrome. Glaudemans AW, Slart RH and Pruim J. Eur J Haematol 2011;87:379.

35. Changes in nutritional status and dietary intake during and after head and neck cancer treatment. Jager-Wittenaar H, Dijkstra PU, Vissink A, Langendijk JA, van der Laan BF, Pruim J and Roodenburg JL. Head Neck 2011;33:863-870.

36. 18F-FLT-PET for detection of rectal cancer. Muijs CT, Beukema JC, Widder J, van den Bergh AC, Havenga K, Pruim J and Langendijk JA. Radiother Oncol 2011;98: 357-359.

37. Tyrosine positron emission tomography and protein synthesis rate in pituitary adenoma: different effects of surgery and radiation therapy. van den Bergh AC, Pruim J, Links TP, van der Vliet AM, Sluiter W, Wolffenbuttel BH, Langendijk JA, Hoving EW and Dullaart RP. Radiother Oncol 2011;98:213-216.

38. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. van Heijl M, Omloo JM, Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch

10

OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW and van Lanschot JJ. Ann Surg 2011;253:56-63.

39. 18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. Wiegman EM, Pruim J, Ubbels JF, Groen HJ, Langendijk JA and Widder J. Eur J Nucl Med Mol Imaging 2011;38:1059-1063.

40. Reduction of artefacts caused by hip implants in CT-based attenuation-corrected PET images using 2-D interpolation of a virtual sinogram on an irregular grid. Abdoli M, de Jong JR, Pruim J, Dierckx RA and Zaidi H. Eur J Nucl Med Mol Imaging 2011;38:2257-2268.

2010 41. Detection of cervical metastases with (11)C-tyrosine pet in patients with squamous cell

carcinoma of the oral cavity or oropharynx: A comparison with (18)F-FDG PET. Krabbe CA, van der Werff-Regelink G, Pruim J, van der Wal JE and Roodenburg JL. Head Neck 2010;32 (3):368-374.

42. A systematic review on the role of FDG-PET/CT in tumour delineation and radio-therapy planning in patients with esophageal cancer. Muijs CT, Beukema JC, Pruim J, Mul VE, Groen H, Plukker JT and Langendijk JA. Radiother Oncol 2010;97 (2):165-171.

43. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Wiering B, Adang EM, van der Sijp Jr., Roumen RM, de Jong KP, Comans EF, Pruim J, Dekker HM, Ruers TJ, Krabbe PF and Oyen WJ. Nucl Med Commun 2010;31 (11):938-944.

44. 18F-FDG PET in squamous cell carcinoma of the oral cavity and oropharynx: a study on inter- and intraobserver agreement. Krabbe CA, Pruim J, Scholtens AM, Roodenburg JL, Brouwers AH, Phan TT, Agool A, Dijkstra PU. J Oral Maxillofac Surg 2010;68 (1):21-27.

45. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A and Krause BJ. Eur J Nucl Med Mol Imaging 2010;37 (1):181-200.

46. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, Dierckx RA and de Jong IJ. Int J Radiat Oncol Biol Phys 2010;77 (1):160-164.

2009 47. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous

cell carcinoma: a prospective study. Krabbe CA, Pruim J, Dijkstra PU, Balink H, van der Laan BF, de Visscher JG and Roodenburg JL. J Nucl Med 2009;50 (12):1940-1947.

48. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Muijs CT, Schreurs LM, Busz DM, Beukema JC, van der Borden AJ, Pruim J, Van der Jagt EJ, Plukker JT and Langendijk JA. Radiother Oncol 2009;93 (3):447-453.

49. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. Ruers TJ, Wiering B, van der Sijp Jr, Roumen RM, de Jong KP, Comans EF, Pruim J, Dekker HM, Krabbe PF and Oyen WJ. J Nucl Med 2009;50 (7):1036-1041.

11

50. High plasma phenylalanine decreases cerebral protein synthesis. Hoeksma M, Reijngoud DJ, Pruim J, de Valk HW, Paans AM, van Spronsen F. Mol Genet Metab 2009;96 (4):177-182.

51. Visualization of small glottic laryngeal cancer using methyl-labeled 11C-methionine positron emission tomography. Wedman J, Pruim J, Langendijk JA and van der Laan BF. Oral Oncol 2009;45 (8):703-705.

52. FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: A comparison with chest radiography and chest CT. Krabbe CA, Pruim J, van der Laan BF, Rodiger LA and Roodenburg JL. Oral Oncol 2009;45(3):234-40.

53. Haemodialysis is associated with a pronounced fall in myocardial perfusion. Dasselaar J, Slart RHJA, Knip M, Pruim J, Tio RA, McIntyre CW, de Jong PE and Franssen CFM. Nephrology Dialysis Transplantation 2009;24(2):604-610.

2008 54. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).

van Heijl M, Omloo JM, van Berge Henegouwen MI, Busch OR, Tilanus HW, Bossuyt PM, Hoekstra OS, Stoker J, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp, HJ, Plukker JT, Bilgen EJ, Ten Kate FJ, Boellaard R, Pruim J, Sloof GW and van Lanschot JJ. BMC Med Phys 2008;8 3-9.

55. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Boellaard R, Oyen WJG, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, Arends B, Verzijlbergen FJ, Zijlstra J, Paans AM, Comans EFI and Pruim J. Eur J Nucl Med Molec Imag 2008;35(12):2320-2333.

56. What is the value of emission tomography studies in patients with a primary glioblastoma multiforme treated by Ir-192 brachytherapy? Koot RW, Habraken JBA, Hulshof MCCM, Paans AMJ, Bosch DA, and Pruim J. Acta Neurochirurgica 2008;150(4):345-349.

57. Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial. Senft A, de Bree R, Hoekstra OS, Kuik DJ, Golding RP, Oyen WJG, Pruim J, den Hoogen FJ, Roodenburgh JLN, Leemans CR. Radiother Oncol 2008;87(2):221-229.

58. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: A clinical and FDOPA-PET study. van Beilen M, Portman AT, Kiers HAL, Maguire RP, Kaasinen V, Koning M, Pruim J, Leenders KL. Parkinsonism Relat Disord 2008;14(3):224-228.

59. FDG PET in oral and oropharyngeal cancer. Value for confirmation of N0 neck and detection of occult metastases. Krabbe CA, Dijkstra PU, Pruim J, van der Laan BFM, van der Wal JE, Gravendeel JP, Roodenburg, JLN. Oral Oncol 2008;44(1):31-36.

60. Cortico-thalamic activation in generalized status epilepticus, a PET study. de Jong BM, van de Hoeven JH, Pruim J, Meertens JH, van der NJ. Clin Neurol Neurosurg 2008;110(2):182-185.

2007 61. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose

positron emission tomography in resectable non-small cell lung cancer: a two-center study. de Jong WK, Van der Heijden HF, Pruim J, Dalesio O, Oyen WJ, Groen HJ. J Thorac Oncol 2007;2(11):1007-1012.

62. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. de Geus-Oei LF, Van der Heijden HF, Visser EP et al. J Nucl Med 2007;48(10):1592-1598.

63. Relative blood volume changes underestimate total blood volume changes during hemodialysis. Dasselaar JJ, Lub-de Hooge MN, Pruim J et al. Clin J Am Soc Nephrol

12

2007;2(4):669-674. 64. Quantification of FDG PET studies using standardised uptake values in multi-centre trials:

effects of image reconstruction, resolution and ROI definition parameters. Westerterp M, Pruim J, Oyen W et al. Eur J Nucl Med Mol Imaging 2007; 34(3):392-404.

65. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Schot BW, Zijlstra JM, Sluiter WJ et al. Blood 2007; 109(2):486-491.

2006 66. Fluordeoxyglucose positron emission tomography contributes to management of pediatric liver

transplantation candidates with fever of unknown origin. Sturm E, Rings EHHM, Scholvinck EH, Gouw ASH, Porte RJ and Pruim J. Liver Transplantation 2006;12(11):1698-1704.

67. Regional cerebral blood flow changes associated with clitorally induced orgasm in healthy women. Georgiadis JR, Kortekaas R, Kuipers R et al. Eur J Neurosci 2006; 24(11):3305-3316.

68. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Bakker NA, Pruim J, de GW, van Son WJ, van der Jagt EJ, van Imhoff GW. Am J Transplant 2006;6(8):1984-1985.

69. Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. de Geus-Oei LF, Visser EP, Krabbe PF et al. J Nucl Med 2006;47(6):945-949.

70. Striatal dopa and glucose metabolism in PD patients with freezing of gait. Bartels AL, de Jong BM, Giladi N et al. Mov Disord 2006;21(9):1326-1332.

71. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H et al. J Clin Oncol 2006; 24(12):1800-1806.

72. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Schot BW, Pruim J, van Imhoff GW, Sluiter WJ, Vaalburg W, Vellenga E. Haematologica 2006; 91(4):490-495.

73. The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases. Kramer H, Post WJ, Pruim J, Groen HJ. Lung Cancer 2006; 52(2):213-217.

2005 74. Assessment of methylphenidate-induced changes in binding of continuously infused [(11)C]-

raclopride in healthy human subjects: correlation with subjective effects. Udo de Haes JI, Kortekaas R, Van Waarde A, Maguire RP, Pruim J, den Boer JA. Psychopharmacology (Berlin) 2005;183(3):322-330.

75. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. van Oostrom JCH, Maguire RP, Verschuuren-Bemelmans CC, Veenma-van der Duin L, Pruim J, Roos RA, Leenders KL. Neurology 2005; 65(6):941-943.

76. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation.Hilker R, Portman AT, Voges J, Staal MJ, Burghaus L, van Laar T, Koulousakis A, Maguire RP, Pruim J, de Jong BM, Herholz K, Sturm V, Heiss WD, Leenders KL. Journal of Neurology Neurosurgery and Psychiatry 2005; 76(9):1217-1221.

77. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, de Jong IJ. European Journal of Nuclear Medicine and Molecular Imaging. 2005; 32(6):668-673.

2004

13

78. Prediction of survival and therapy outcome with C-11-tyrosine PET in patients with laryngeal carcinoma. de Boer JR, Pruim J, Albers FWJ, Burlage F, Vaalburg W, van der Laan BFAM. Journal of Nuclear Medicine 2004; 45(12):2052-2057.

79. PET neuroimaging and mutations in the DJ-1 gene. Dekker MCJ, Eshuis SA, Maguire RP, Veenma-van der Duijn L, Pruim J, Snijders PJLM, Oostra BA, van Duijn CM, Leenders KL. Journal of Neural Transmission 2004; 111(12):1575-1581.

80. Systematic review of the staging performance of F-18-fluorodeoxyglucose positron emission tomography in esophageal cancer. van Westreenen HL, Westerterp M, Bossuyt PMM, Pruim J, Sloof GW, van Lanschot JJB, Groen H, Plukker JTM. Journal of Clinical Oncology 2004; 22(18):3805-3812.

81. PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. Tio RA, Tan ES, Jessurun GAJ, Veeger N, Jager PL, Slart RHJA, de Jong RM, Pruim J, Hospers GAP, Willemsen ATM, de Jongste MJL, van Boven AL, van Veldhuizen DJ, Zijlstra F. J Nucl Med. 2004; 45(9):1437-1443.

82. Oesophageal endoscopic ultrasound with fine needle aspiration improves and simplifies the staging of lung cancer. Kramer H, van Putten JWG, Post WJ, van Dullemen HM, Bongaerts AHH, Pruim J, Suurmeijer AJH, Klinkenberg TJ, Groen H, Groen HJM. Thorax 2004; 59(7):596-601.

83. Source of impaired image quality in 3D whole-body FDG PET scanning. Paans AMJ, Boerdijk SMM, Willemsen ATM, Pruim J. European Journal of Nuclear Medicine and Molecular Imaging 2004; 31(8):1207.

2003 84. Predictive value of early F-18-fluoro-deoxyglucose positron emission tomography in

chemosensitive relapsed lymphoma. Schot B, van Imhoff G, Pruim J, Sluiter W, Vaalburg W, Vellenga E. British Journal of Haematology 2003; 123(2):282-287.

85. Therapy evaluation of laryngeal carcinomas by tyrosine-PET. de Boer JR, Pruim J, Burlage F, Krikke A, Tiebosch ATMG, Albers FWJ et al. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 2003; 25(8):634-644.

86. C-11-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. European Urology 2003; 44(1):32-38.

87. Cerebral perfusion and metabolism in resuscitated patients with severe post-hypoxic encephalopathy. Schaafsma A, de Jong BM, Bams JL, Haaxma-Reiche H, Pruim J, Zijlstra JG. Journal of the Neurological Sciences. 2003; 210(1-2):23-30.

88. Preoperative staging of pelvic lymph nodes in prostate cancer by C-11-choline PET. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Journal of Nuclear Medicine. 2003; 44(3):331-335.

89. L-1-C-11-tyrosine PET in patients with laryngeal carcinomas: Comparison of standardized uptake value and protein synthesis rate. de Boer JR, Pruim J, van der Laan BFAM, Que TH, Willemsen ATM, Albers FWJ et al. Journal of Nuclear Medicine. 2003; 44(3):341-346.

2002 90. Liver metastasis as a first sign of Fallopian tube carcinoma and the role of positron emission

tomography in preoperative diagnosis. van Leeuwen BL, Pruim J, Gouw ASH, van der Zee AGJ, Sloof MJH, de Jong KP. Scandinavian Journal of Gastroenterology. 2002; 37(12):1473-1474.

14

91. Visualisation of bladder cancer using C-11-choline PET: first clinical experience. de Jong IJ, Pruim J, Elsinga PH, Jongen MMGJ, Mensink HAJ, Vaalburg W. European Journal of Nuclear Medicine and Molecular Imaging. 2002; 29(10):1283-1288.

92. 5-HT1A receptor imaging in the human brain: Effect of tryptophan depletion and infusion on [F-18]MPPF binding. De Haes JIU, Bosker FJ, van Waarde A, Pruim J, Willemsen ATM, Vaalburg W et al. Synapse. 2002; 46(2):108-115.

93. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BFAM, Vaalburg W et al. European Journal of Nuclear Medicine and Molecular Imaging. 2002; 29(8):1024-1030.

94. Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas. de Boer JR, van der Laan BFAM, Pruim J, Que TH, Burlage F, Krikke A et al. European Journal of Nuclear Medicine and Molecular Imaging. 2002; 29(9):1182-1187.

95. Positron emission tomography: measurement of myocardial perfusion using N-13-labeled ammonia and O-15-labeled water. Blanksma PK, Pruim J. Methods. 2002; 27(3):226-227.

96. Visualization of prostate cancer with C-11-choline positron emission tomography. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. European Urology. 2002; 42(1):18-23.

97. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. van Tol KM, Jager PL, Piers DA, Pruim J, de Vries EGE, Dullaart RPF et al. Thyroid. 2002; 12(5):381-387.

98. Effects of fibroblast growth factor and glial-derived neurotrophic factor on akinesia, F-DOPA uptake and dopamine cells in parkinsonian primates. Fontan A, Rojo A, Sanchez Pernaute R, Hernández I, López I, Castilla C, Sanchez Albisua J, Perez Higueras A, Al-Rashid I, Rabano A, Gonzalo I, Mena MA, Cools A, Eshuis S, Maguire P, Pruim J, Leenders K, Garcia de Yebenes J. Parkinsonism & Related Disorders 2002; 8(5):311-323.

99. Quantification of beta-adrenoceptor density in the human heart with (S)-[C-11]CGP 12388 and a tracer kinetic model. Doze P, Elsinga PH, van Waarde A, Pieterman RM, Pruim J, Vaalburg W et al. European Journal of Nuclear Medicine and Molecular Imaging. 2002; 29(3):295-304.

100.Visualisation and assessment of the protein synthesis rate of lung cancer using carbon-11 tyrosine and positron emission tomography. Pieterman R, Willemsen A, Appel M, Pruim J, Koeter G, Vaalburg W et al. European Journal of Nuclear Medicine and Molecular Imaging. 2002; 29(2):243-247.

101.Comparison of C-11-choline and F-18-FDG PET in primary diagnosis and staging of patients with thoracic cancer. Pieterman RM, Que TH, Elsinga PH, Pruim J, van Putten JWG, Willemsen ATM et al. Journal of Nuclear Medicine. 2002; 43(2):167-172.

2001 102.Carbon-11 choline or FDG-PET for staging of oesophageal cancer? Jager PL, Que TH, Vaalburg

W, Pruim J, Elsinga P, Plukker JT. European Journal of Nuclear Medicine. 2001; 28(12):1845-1849.

103.Patient management guided by viability imaging - Reply. Siebelink HMJ, Blanksma PK, Crijns HJGM, Bax JJ, van Boven AJ, Kingma T et al. Journal of the American College of Cardiology. 2001; 38(4):1272-1273.

104.The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Portman AT, Giladi N, Leenders KL, Maguire P, Veenma-van der Duin L, Swart J et al. Neurology. 2001; 56(12):1759-1762.

105.Radiolabeled amino acids: Basic aspects and clinical applications in oncology. Jager PL,

15

Vaalburg W, Pruim J, de Vries EGE, Langen KJ, Piers DA. Journal of Nuclear Medicine. 2001; 42(3):432-445.

106. No difference in cardiac event-free survival between positron emission tomography- guided and single-photon emission computed tomography-guided patient management - A prospective, randomized comparison of patients with suspicion of jeopardized myocardium. Siebelink HMJ, Blanksma PK, Crijns HJGM, Bax JJ, van Boven AJ, Kingma T et al. Journal of the American College of Cardiology. 2001; 37(1):81-88.

2000 107.Similar cardiac event free survival in PET and SPECT based patient management. Siebelink HMJ,

Blanksma PK, Crijns HJGM, Bax JJ, van Boven AJ, Kingma T et al. Circulation. 2000; 102(18):770-771.

108. Language localization in cases of left temporal lobe arachnoid cyst: Evidence against interhemispheric reorganization. Stowe LA, Go KG, Pruim J, den Dunnen W, Meiners LC, Paans AMJ. Brain and Language. 2000; 75(3):347-358.

109. In vivo delineation of 5-HT1A receptors in human brain with [F-18]MPPF. Passchier J, van Waarde A, Pieterman RM, Elsinga PH, Pruim J, Hendrikse HN et al. Journal of Nuclear Medicine. 2000;41(11):1830-1835.

110. Quantitative imaging of 5-HT1A receptor binding in healthy volunteers with [F-18]p-MPPF. Passchier J, van Waarde A, Pieterman RM, Elsinga PH, Pruim J, Hendrikse HN et al. Nuclear Medicine and Biology 2000;27(5):473-476.

111. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. Pieterman RM, van Putten JWG, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH et al. New England Journal of Medicine. 2000; 343(4):254-261.

112. Evaluation of dissemination studies with FDG whole-body positron emission tomography in patients with suspected metastatic tumours of brain and spine. Go KG, Pruim J, Que TH, Vaalburg W, Haaxma-Reiche H. Acta Neurochirurgica. 2000; 142(6):627-631.

113. Acute effects of thalamotomy and pallidotomy on regional cerebral metabolism, evaluated by PET. Henselmans JML, de Jong BM, Pruim J, Staal MJ, Rutgers AWF, Haaxma R. Clinical Neurology and Neurosurgery. 2000; 102(2):84-90.

1999 114. Measurement of clinical and subclinical tumour response using [F-18]-fluorodeoxyglucose and

positron emission tomography: Review and 1999 EORTC recommendations. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA et al. European Journal of Cancer. 1999; 35(13):1773-1782.

115. Regional specific changes of cerebral metabolism in systemic lupus erythematosus identified by positron emission tomography. de Jong BM, Pruim J, Sinnige LGF, Beintema KD, Spronk PE, Bootsma H et al. European Neurology. 1999; 41(4):187-193.

116. Noninvasive detection of inguinofemoral lymph node metastases in squamous cell cancer of the vulva by L-[1-C-11]-tyrosine positron emission tomography. De Hullu JA, Pruim J, Que TH, Aalders JG, Boonstra H, Vaalburg W et al. International Journal of Gynecological Cancer. 1999; 9(2):141-146.

16

1998 117. L-[1-C-11]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally

advanced soft-tissue sarcoma and skin cancer. van Ginkel RJ, Kole AC, Nieweg OE, Molenaar WM, Pruim J, Koops HS et al. Journal of Nuclear Medicine. 1999; 40(2):262-267. 1998

118. Detection of unknown occult primary tumors using positron emission tomography. Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JLN et al. Cancer. 1998; 82(6):1160-1166.

119. C-11-tyrosine position emission tomography and H-1 magnetic resonance spectroscopy of the response of brain gliomas to radiotherapy. Heesters MAAM, Go KG, Kamman RL, Mooyaart EL, Meertens H, Paans AMJ et al. Neuroradiology. 1998; 40(2):103-108.

1997 120. Proliferative activity in human brain tumors: Comparison of histopathology and L-[1-C-

11]tyrosine PET. De Wolde H, Pruim J, Mastik MF, Koudstaal J, Molenaar WM. Journal of Nuclear Medicine 1997; 38(9):1369-1374.

121. Imaging beta-adrenoceptors in the human brain with (S)-1'-[F-18]fluorocarazolol. van Waarde A, Visser TJ, Elsinga PH, de Jong BM, van der Mark TW, Kraan J et al. Journal of Nuclear Medicine 1997; 38(6):934-939.

122. Coronary vasomotion in patients with syndrome X: Evaluation with positron emission tomography and parametric myocardial perfusion imaging. Meeder JG, Blanksma PK, van der Wall EE, Willemsen ATM, Pruim J, Anthonio RL et al. European Journal of Nuclear Medicine 1997; 24(5):530-537.

123. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-C-11]tyrosine PET. Kole AC, Nieweg OE, Pruim J, Paans AMJ, Plukker JTM, Hoekstra HJ et al. Journal of Nuclear Medicine. 1997; 38(5):692-696.

124. Detection of unknown primary head and neck tumors by positron emission tomography. Braams JW, Pruim J, Kole AC, Nikkels PGJ, Vaalburg W, Vermey A et al. International Journal of Oral and Maxillofacial Surgery. 1997; 26(2):112-115.

125. Cobalt-55 positron emission tomography in ischemic stroke. Jansen HML, Paans AMJ, Vliet AMV, Veenma-van der Duin L, BolwijnMeijer CJW, Pruim J et al. Clinical Neurology and Neurosurgery. 1997; 99(1):6-10.

126. Characterization of pulmonary and myocardial beta-adrenoceptors with S-1'-[fluorine-18]fluorocarazolol. Visser TJ, van Waarde A, van der Mark TW, Kraan J, Elsinga PH, Pruim J et al. Journal of Nuclear Medicine 1997; 38(2):169-174.

127. PET with 1-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates. Kole AC, Pruim J, Nieweg OE, van Ginkel RJ, Hoekstra HJ, Koops HS et al. Journal of Nuclear Medicine. 1997; 38(2):191-195.

128. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [F-18] fluorodeoxyglucose. Kole AC, Nieweg OE, van Ginkel RJ, Pruim J, Hoekstra HJ, Paans AMJ et al. Annals of Surgical Oncology 1997;4(1):57-63.

1996 129. Radiolabelled tyrosine for the measurement of protein synthesis rate in vivo by positron

emission tomography. Paans AMJ, Pruim J, van Waarde A, Willemsen ATM, Vaalburg W. Baillieres Clinical Endocrinology and Metabolism. 1996;10(4):497-510

130. Long-term cigarette smoking is associated with increased myocardial perfusion heterogeneity assessed by positron emission tomography. Meeder JG, Blanksma PK, van der Wall EE,

17

Anthonio RL, Willemsen ATM, Pruim J et al. European Journal of Nuclear Medicine. 1996; 23(11):1442-1447.

131. Comparison between positron emission tomography myocardial perfusion imaging and intracoronary Doppler flow velocity measurements at rest and during cold pressor testing in angiographically normal coronary arteries in patients with one-vessel coronary artery disease. Meeder JG, Peels HO, Blanksma PK, Tan ES, Pruim J, van der Wall EE et al. American Journal of Cardiology. 1996;78(5):526-531.

132. Nodal spread of squamous cell carcinoma of the oral cavity detected with PET-tyrosine, MRI and CT. Braams JW, Pruim J, Nikkels PGJ, Roodenburg JLN, Vaalburg W, Vermey A. Journal of Nuclear Medicine 1996;37(6):897-901.

133. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. van Ginkel RJ, Hoekstra HJ, Pruim J, Nieweg OE, Molenaar WM, Paans AMJ et al. Journal of Nuclear Medicine 1996;37(6):984-990.

134. Effects of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Hautvast RWM, Blanksma PK, De Jongste MJL, Pruim J, van der Wall EE, Vaalburg W et al. American Journal of Cardiology 1996;77(7):462-467.

135. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AMJ, Molenaar WM et al. Journal of Nuclear Medicine 1996; 37(2):257-261.

136. Cobalt-55 positron emission tomography in traumatic brain injury: A pilot study. Jansen H, van der Naalt J, Van Zomeren AH, Paans AMJ, Veenma-van der Duin L, Hew JM et al. Journal of Neurology Neurosurgery and Psychiatry 1996; 60(2):221-224.

1995 137. Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and

heart rate variability. Meeder JG, Blanksma PK, Crijns HJGM, Anthonio RL, Pruim J, Brouwer J et al. European Heart Journal. 1995; 16(11):1571-1577.

138. Comparison of human hepatocytes isolated from livers accepted or discarded for orthotopic transplantation. Groothuis GMM, Sandker GW, Pruim J, Weert B, Slooff MJH, Meijer DKF. Toxicology in Vitro. 1995; 9(6):951-958.

139. Brain-Tumors- L-[1-C-11]Tyrosine PET for Visualization and Quantification of Protein-Synthesis Rate. Pruim J, Willemsen ATM, Molenaar WM, van Waarde A, Paans AMJ, Heesters MAAM et al. Radiology 1995; 197(1):221-226.

140. Cobalt-55 Positron Emission Tomography in Relapsing-Progressive Multiple-Sclerosis. Jansen HML, Willemsen ATM, Sinnige LGF, Paans AMJ, Hew JM, Franssen EJF et al. Journal of the Neurological Sciences. 1995;132(2):139-145.

141. On the Principles Underlying the Diagnosis of Brain-Tumors A Survey Article. Go KG, Kamman RL, Pruim J, Hew JM, Vaalburg W, Paans AMJ et al. Acta Neurochirurgica. 1995;135(1-2):1-11

142. Localized Proton Spectroscopy and Spectroscopic Imaging in Cerebral Gliomas, with Comparison to Positron Emission Tomography. Go KG, Kamman RL, Mooyaart EL, Heesters MAAM, Pruim J, Vaalburg W et al. Neuroradiology 1995; 37(3):198-206.

143. Posterolateral Defect of the Normal Human Heart Investigated with Nitrogen-13-Ammonia and Dynamic PET. de Jong RM, Blanksma PK, Willemsen ATM, Anthonio RL, Meeder JG, Pruim J et al. Journal of Nuclear Medicine 1995;36(4):581-585.

144. In-Vivo Protein-Synthesis Rate Determination in Primary Or Recurrent Brain-Tumors Using L-[1-C-11]-Tyrosine and PET. Willemsen ATM, van Waarde A, Paans AMJ, Pruim J, Luurtsema G, Go

18

KG et al. Journal of Nuclear Medicine 1995;36(3):411-419. 145. Unique Myoclonic Pattern in Corticobasal Degeneration. Brunt ERP, Van weerden TW, Pruim J,

Lakke JWPF. Movement Disorders 1995;10(2):132-142. 146. Detection of Lymph-Node Metastases of Squamous-Cell Cancer of the Head and Neck with

FDG-PET and MRI. Braams JW, Pruim J, Freling NJM, Nikkels PGJ, Roodenburg JLN, Boering G et al. Journal of Nuclear Medicine 1995;36(2):211-216.

147. Quantitative Myocardial Mapping of Perfusion and Metabolism Using Parametric Polar Map Displays in Cardiac PET. Blanksma PK, Willemsen ATM, Meeder JG, de Jong RM, Anthonio RL, Pruim J et al. Journal of Nuclear Medicine 1995;36(1):153-158.

1994 148. Contribution of Magnetic-Resonance Spectroscopic Imaging and L- [1-C-11]Tyrosine Positron

Emission Tomography to Localization of Cerebral Gliomas for Biopsy. Go KG, Keuter EJW, Kamman RL, Pruim J, Metzemaekers JDM, Staal MJ et al. Neurosurgery 1994;34(6):994-1002.

149. Visualization of Damaged Brain-Tissue After Ischemic Stroke with Cobalt-55 Positron Emission Tomography. Jansen HML, Pruim J, Van der vliet AM, Paans AMJ, Hew JM, Franssen EJF et al. Journal of Nuclear Medicine 1994;35(3):456-460.

150. Positron Emission Tomography with Fluorine-18-Fluorodeoxyglucose for the Evaluation of Therapeutic Isolated Regional Limb Perfusion in A Patient with Soft-Tissue Sarcoma. Nieweg OE, Pruim J, Hoekstra HJ, Paans AMJ, Vaalburg W, Oldhoff J et al. Journal of Nuclear Medicine 1994;35(1):90-92.

151. Dopamine (D-2-)Receptor Binding in Patients Treated with Clozapine As Measured Bij Positron Emission Tomography Using (18)FESP. Louwerens JW, Buddingh JA, Zijlstra S, Pruim J , Korf J, Paans A et al. Schizophrenia Research 1994;11(2):165-166.

1993 152. Donor Criteria for Liver-Transplantation - A Comparative-Study of the Effects of Donor Liver

Selection. Pruim J, ten Vergert EM, de Kempenaer MGV, Bonsel GJ, Slooff MJH. Clinical Transplantation 1993;7(5):447-452.

153. Cystic Lesions of the Brain - A Classification Based on Pathogenesis, with Consideration of Histological and Radiological Features. Go KG, Hew JM, Kamman RL, Molenaar WM, Pruim J, Blaauw EH. European Journal of Radiology 1993;17(2):69-84.

154. Pruim J, Klompmaker IJ, Haagsma EB, Bijleveld CMA, Slooff MJH. Selection Criteria for Liver Donation - A Review. Transplant International 1993;6(4):226-235.

1992 155. Experience of Bereaved Relatives Who Granted Or Refused Permission for Organ Donation.

Tymstra T, Heyink JW, Pruim J, Slooff MJH. Family Practice 1992;9(2):141-144. 1991 156. Cellular-Damage and Early Metabolic Function of Transplanted Livers Stored in Eurocollins Or

University-Of-Wisconsin Solution. Pruim J, ten Vergert EM, Klompmaker IJ, Verwer R, Slooff MJH. European Surgical Research 1991;23(5-6):285-291.

157. Organ Donation from Trauma Victims. Werkman HA, Pruim J, ten Vergert EM, ten Duis HJ, Slooff MJH. Transplantation Proceedings 1991;23(5):2553-2554.

19

1989 158. Donor Data in Liver Grafts with Primary Non-Function - A Preliminary-Analysis by the European

Liver Registry. Pruim J, van Woerden WF, Knol E, Klompmaker IJ, de Bruijn KM, Persijn GG et al. Transplantation Proceedings 1989;21(1):2383-2384.

159. Hepatic-Artery Thrombosis After Orthotopic Liver-Transplantation - A Fatal Complication Or An Asymptomatic Event. Hesselink EJ, Klompmaker IJ, Pruim J, van Schilfgaarde R, Slooff MJH. Transplantation Proceedings 1989;21(1):2462.

1988 160. The Validity of Clinical-Parameters for the Selection of Liver-Donors. Pruim J, Hesselink EJ, de

Vos R, Klompmaker IJ, de Bruijn KM, Grond J et al. Transplantation Proceedings 1988;20(5):973.

Abstracts Author or co-author of over 200 international congress abstracts. Book chapters - Good Clinical Practice and Nuclear Medicine. In: Elsinga PH, van Waarde A, Paans AMJ, Dierckx

RAJO, eds. Trends on the Role of PET in Drug Development. Glaudemans AWJM, Dierckx RAJO, Otte A, Kusić Z, Pruim J, De Deyn PP. Singapore 2012, World Scientific Publishing Co, pp. 691-725. ISBN-13 978-981-4317-73-3.

- Application of PET in the diagnosis and treatment evaluation of soft tissue sarcomas. In: Paans AMJ, Pruim J, Franssen EFJ, Vaalburg W, eds. Metabolic Imaging of Cancer, Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology. Van Ginkel RJ, Kole AC, Nieweg OE, Pruim J, Molenaar WM, Paans AMJ, Willemsen ATM, Vaalburg W, Schraffordt Koops H, Hoekstra HJ. Groningen 1996, Academisch Ziekenhuis Groningen, pp. 15-18. ISBN 90-802859-1-9.

- Protein synthesis rate: evaluation of cytotoxic therapy in lung cancer using L-[1-11C]-tyrosine and positron emission tomography. In: Paans AMJ, Pruim J, Franssen EFJ, Vaalburg W, eds. Metabolic Imaging of Cancer, Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology. Appel M, Pruim J, van der Mark TW, Willemsen ATM, Smit EF, Paans AMJ, Koëter GH, Vaalburg W. Groningen 1996, Academisch Ziekenhuis Groningen, pp 22-24. ISBN 90-802859-1-9.

- Positron emission tomography (PET) in head and neck oncology. In: Paans AMJ, Pruim J, Franssen EFJ, Vaalburg W, eds. Metabolic Imaging of Cancer, Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology. Braams JW, Pruim J, Nikkels P, Vaalburg W, Roodenburg JLN, Vermey A. Groningen 1996, Academisch Ziekenhuis Groningen, pp. 42-43. ISBN 90-802859-1-9.

- Detection of local recurrence of malignant neoplasms with PET and FDG. In: Paans AMJ, Pruim J, Franssen EFJ, Vaalburg W, eds. Metabolic Imaging of Cancer, Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology. Nieweg OE, Kole AC, Pruim J, Hoekstra HJ, van Ginkel RJ, Schraffordt Koops H, Vaalburg W. Groningen 1996, Academisch Ziekenhuis Groningen, pp. 53-54. ISBN 90-802859-1-9.

- Imaging of primary brain tumors with 2-[11C]-thymidine. A comparison with L-[11C]-tyrosine positron emission tomography. In: Paans AMJ, Pruim J, Franssen EFJ, Vaalburg W, eds. Metabolic Imaging of Cancer, Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology.

20

Franssen EFJ, Pruim J, Go KG, Heesters MAAM, Paans AMJ, Vaalburg W. Groningen 1996, Academisch Ziekenhuis Groningen, pp. 119-120. ISBN 90-802859-1-9.

- Detection of unknown primary tumors using whole body PET with 18FDG. In: Paans AMJ, Pruim J, Franssen EFJ, Vaalburg W, eds. Metabolic Imaging of Cancer, Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology. Kole AC, Nieweg OE, Vermey A, Braams JW, Pruim J, Hoekstra HJ, Roodenburg JLN, Schraffordt Koops H, Vaalburg W. Groningen 1996, Academisch Ziekenhuis Groningen, pp. 135-136. ISBN 90-802859-1-9.

7.3 EDITOR TEXTBOOKS

- Imaging of Cancer, Proceedings of the European Conference on Research and Application of

Positron Emission Tomography in Oncology. Paans AMJ, Pruim J, Franssen EFJ, Vaalburg W, eds. Metabolic. Groningen 1996, Academisch Ziekenhuis Groningen. ISBN 90-802859-1-9.

- Overleveren, 10 jaar levertransplantatie in Groningen. Pruim J, ed. Groningen 1990, Academisch Ziekenhuis Groningen. ISBN 90-5252-005-4.

- Handboek Orgaanverwerving. Groningen 1988, Afdeling Chirurgie, Academisch Ziekenhuis Groningen. Van Goor H, Pruim J, Slooff MJH. ISBN 90-5252-001-1.

7.4 INVITED LECTURES

2018 (1) May 26, 2nd Nuclear Medicine Symposium, Baku, Azerbaidzjan, Title: The Future of Nuclear

Medicine: Sky is the Limit (2) March 24, 2nd CME Symposium PET/CT in Oncology: From basic science to clinical sense, Karachi,

Pakistan. Title: Positron Emission Tomography in the Diagnosis and Treatment of Head and Neck Cancer.

(3) March 24, 2nd CME Symposium PET/CT in Oncology: From basic science to clinical sense, Karachi, Pakistan. Title: Positron Emission Tomography in the Diagnosis and Treatment of Lung Cancer.

(4) March 24, 2nd CME Symposium PET/CT in Oncology: From basic science to clinical sense, Karachi, Pakistan. Title: Radionuclides in the Diagnosis and Treatment of Prostate Cancer.

2017

(5) June 13, Society of Nuclear Medicine and Molecular Imaging, Denver CO, United States of America. Title: ‘The Medical Imager of the Future.’

2016 (6) September 23, South-African Society of Nuclear Medicine, Pretoria, South-Africa.

Title: ‘New Dutch Radiology Training’. (7) April 15, XXI Encontro de Medicina Nuclear do CHUC. Medical Training – Quo Vadis Medicina

Nuclearis? Coimbra, Portugal. Title: ‘Nuclear Medicine training in Holland’.

21

2014 (8) September 21, South-African Society of Nuclear Medicine, Durban, South-Africa.

Title: ‘The use of FDG-PET/CT and hypoxia markers in radiotherapy planning’. (9) September 19, South-African Society of Nuclear Medicine, Durban, South-Africa.

Title: ‘Fluor tracers beyond FDG’. (10) September 19, South-African Society of Nuclear Medicine, Durban, South-Africa.

Title: ‘The Use of PET-labeled Monoclonal Antibodies (with Emphasis on 89Zr)’. (11) September 16, University of Pretoria/Steve Biko Academic Hospital, Pretoria, South-Africa.

Title: ‘Nuclear Medicine and Radiology Combined. Towards a new curriculum’. (12) April 14, University Putra Malaysia CME Programme “Dementia”.

Title: ‘Degenerative brain disorders’. (13) April 12, University Putra Malaysia & Malaysian College of Radiology Dialogue Session.

Title: “Nuclear Medicine and Radiology Combined Towards a New Curriculum”. (14) April 8, University Putra Malaysia CME Programme “Standardization of PET-CT

Imaging Technique”. Title: ‘Standardization of PET-CT: man, machine and procedures’.

(15) April 3, 2014 Malaysian College of Radiology Scientific Meeting & Korean Society

of Radiology – McoR Friendship Symposium, Putrajaya, Malaysia. Title: The Role of PET-CT in Cardiovascular Imaging.

(16) April 3, 2014 Malaysian College of Radiology Scientific Meeting & Korean Society of Radiology – McoR Friendship Symposium, Putrajaya, Malaysia. Title: Oncology Imaging using Beyond 18F-FDG Tracers.

(17) April 3, 2014 Malaysian College of Radiology Scientific Meeting & Korean Society of Radiology – MCoR Friendship Symposium, Putrajaya, Malaysia. Title: The role of FDG-PET in Breast Cancer.

2013 (18) February 27, Tygerberg Hospital Cape Town/University of Stellenbosch.

Title: ‘18F beyond FDG’ and ‘RSNA Chicago 2012’.

2012 (19) November 9, Scientific Meeting of the Dutch Society of Nuclear Medicine.

Title: ‘New radiopharmaceuticals: 18F-tracers’. (20) April 18, Tygerberg Hospital Cape Town/University of Stellenbosch.

Titles: ‘Positron Emission Tomography (PET) in Radiation Oncology’ and `SUV: Silly or Standard’.

2011 (21) September 9, Vienna, IAEA.

Title: ‘11C-labeled radiopharmaceuticals: sky is the limit?’

2010 (22) September 22, Cape Town, 10th Congress of the World Federation of Nuclear Medicine

and Biology. Title: ‘GCP in Nuclear Medicine – Quality through Transparency’.

(23) February 25, University of South Bohemia Ceske Budejovice, Czech Republic.

22

Titles: ‘Scintigraphic Diagnostics Of Infection and Inflammation In Orthopedics’; and: ‘Scintigraphic Diagnostics Of Neuroendocrine Tumors’ (Erasmus Exchange).

2009 (24) July 2, Hospital Miloszdrice, Zagreb University, Zagreb, Croatia.

Titles: ‘Positron Emission Tomography (PET) for Radiotherapeutic Planning’; ‘SUV: silly or standard? Standardization of image acquisition and analysis in multicenter studies’; and ‘Iodine treatment in thyroid cancer and hyperthyroidism; the Dutch approach’.

2008 (25) October 12, Munich, Annual Congress of the European Association of Nuclear Medicine.

Title: ‘SUV: silly or standard? Standardization of image acquisition and analysis in multicenter studies’.

(26) April 9, London, Symposium on Drug Development. Title: ‘Molecular Imaging in Drug Research’.

2001 (27) November, Washington DC, International Congress on Neuro-Oncology.

Title: ‘Brain tumour imaging with positron emission tomography’.

7.5 SUPERVISOR OF PhD THESIS - DuToit M. Tumor delineation and characterization using multi-tracer and multi-parametric PET/CT

data. Supervisors: Pruim J, Ellmann A, Dierckx RAJO, co-supervisor: Koole M. University of Groningen (in co-operation with Stellenbosch University, South-Africa), (in progress).

- Wondergem M. Exploring new molecular imaging concepts of prostate cancer. Supervisors: De Jong IJ, Pruim J, co-supervisor: van Zanten FM. University of Groningen, November 20, 2017.

- Kerner GSMA. Imaging and clinical outcome of non-small cell lung cancer. Supervisors: Groen HJM, Pruim J. University of Groningen, May 11, 2016.

- Bollineni VR. FDG- and FAZA-PET in head-and-neck cancer patients treated with radiotherapy. Supervisors: Langendijk H, Pruim J. Co-supervisor: Steenbakkers RJHM. University of Groningen, January 14, 2014.

- Abdoli M. Development and Evaluation of Metal Artefact Reduction and Image Segmentation Techniques in PET/CT. Supervisors: Zaidi H, Dierckx RAJO, Pruim J. University of Groningen, October 2, 2013.

7.6 CO-SUPERVISOR OF PhD THESIS

- Krabbe CA. Positron emission tomography in staging and surveillance of oral and oropharyngeal squamous cell carcinoma. Supervisors: Roodenburg JLN, Dijkstra PU. Co-supervisor: Pruim J. University of Groningen, October 6, 2010.

- Breeuwsma AJ. Molecular medicine in staging and restaging of prostate cancer. supervisors: Nijman JM, Dierckx RAJO. Co-supervisors: de Jong IJ, Pruim J. University of Groningen, September 2, 2009.

- Schot BW. Positron emission tomography in malignant haematological disease. Supervisors: Vellenga E, Vaalburg W. Co-supervisors: Pruim J, van Imhoff GW. University of Groningen, October 10, 2007.

- De Boer JR. Clinical applications of L-[1-11C]-tyrosine PET in laryngeal cancer. Supervisors: Albers

23

FWJ, Vaalburg W. Co-supervisors: van der Laan BFAM, Pruim J. University of Groningen, March 7, 2007.

- Pieterman RM. Detection, staging and follow up of lung cancer with positron emission tomography. Supervisors: Vaalburg W, Groen HJM, Koëter GH. Co-supervisor: Pruim J. University of Groningen, September 10, 2003.

- De Jong IJ. Positron emission tomography in urologic oncology. On the application of 11C-labeled radiopharmaceuticals in prostate and bladder cancer. Supervisors: Mensink HJA, Vaalburg W. Co-supervisor: Pruim J. University of Groningen, January 22, 2003.

- Braams JW. Positron emission tomography (PET) in head and neck oncology. Supervisors: Roodenburg JLN, Vaalburg W, Vermey A. Co-supervisors: Nikkels PGJ, Pruim J. University of Groningen, September 30, 1998.

PhD Reading Committee - Frings V. In vivo quantification of proliferation and glucose metabolism in lung cancer patients. VU

University Medical Center, 2014. - Catalano O. PET/MR imaging of neoplastic and inflammatory lesions. University of Groningen,

2018. - Van Dijk LV. Predicting salivary gland dysfunction with image biomarkers in head and neck

patients. University of Groningen, 2018.

7.7 MEMBERSHIPS - Dutch Society for Nuclear Medicine (Nederlandse Vereniging voor Nucleaire Geneeskunde, 1996) - Society of Nuclear Medicine and Molecular Imaging (1992) - European Association of Nuclear Medicine (1998) - Royal Dutch Medical Association (Koninklijke Nederlandsche Maatschappij tot bevordering der

Geneeskunst 1984)

8. REVIEWER

8.1 JOURNALS - European Journal of Nuclear Medicine & Molecular Imaging - Journal of Nuclear Medicine - Nuclear Medicine Communications

9. MISCELLANEOUS

9.1 PARTICULAR SOCIETAL CONTRIBUTIONS 2011-current Founder and 1st chairman of the “Vrienden van de Kloosterkerk” Foundation.

Aim of the foundation is to preserve the 13th century Kloosterkerk in Ten Boer for posteriority, and to organize cultural events in the church.

2003-2007 President of Church Council of the Dutch Reformed Church of Ten Boer – Sint Annen (nowadays Kloosterkerkgemeente Ten Boer – Woltersum – Sint Annen).

24

9.2 HOBBIES - Photography - Classical music

9.3 REFERENCES Prof. dr. R.A.J.O. Dierckx, Department of Nuclear Medicine, Medical Imaging Center, University Medical Center Groningen Prof. Valerie Lewington, Former Chair European School for Nuclear Medicine

1985-1988 Phycisian Dutch Red Cross Corps, Bedum, The Netherlands. Voluntary work to train lay people as first aid helpers in catastrophic circumstances.